June 16, 2022

Cerevance to Present During the 5th Annual LSX World Congress USA

What’s a Rich Text element?

The rich text element allows you to create and format headings, paragraphs, blockquotes, images, and video all in one place instead of having to add and format them individually. Just double-click and easily create content.

Static and dynamic content editing

A rich text element can be used with static or dynamic content. For static content, just drop it into any page and begin editing. For dynamic content, add a rich text field to any collection and then connect a rich text element to that field in the settings panel. Voila!

How to customize formatting for each rich text

Headings, paragraphs, blockquotes, figures, images, and figure captions can all be styled after a class is added to the rich text element using the "When inside of" nested selector system.

Boston, MA – June 16, 2022 – Cerevance, a private, clinical-stage drug discovery and development company focused on central nervous system (CNS) diseases, today announced that Carrie Cook, chief business officer (CBO) of Cerevance, will participate in a fireside chat during the 5th Annual LSX World Congress USA being held in Boston, MA, June 21-22. Ms. Cook will share her thoughts around the evolving mergers and acquisitions (M&A) landscape, including how to prepare for a successful merger and how to best integrate teams and cultures from both parties involved.

Presentation Details:

Title: “Expert Insight Fireside chat: Merging of teams, cultures and assets – when M&A makes sense and how to prepare”
Wednesday, June 22, 2022
3:30 p.m. ET

  • Craig Thompson, M.B.A. – CEO of Cerevance
  • Dolo Diaz, Ph.D. – VP, Development Sciences of Denali Therapeutics
  • Dhivya Venkat – CEO of Esya Labs
  • Amit Etkin, M.D., Ph.D. – Co-Founder and CEO of Alto Neuroscience

For more information and registration details, see the LSX website here.

About Cerevance

Cerevance is a private pharmaceutical company whose lead therapeutic, CVN424, a first-in-class compound acting on a novel target, recently demonstrated significant and clinically meaningful efficacy in a 135-patient phase 2 study in Parkinson’s Disease. The company uses its proprietary NETSseq platform to highly selectively identify novel target proteins that are either over- or under-expressed. Partnering with over 20 brain banks and evaluating more than 11,000 brain tissue samples, Cerevance is advancing therapeutics with novel mechanisms of action for diseases such as Parkinson’s, amyotrophic lateral sclerosis (ALS), and Alzheimer’s. For additional information, please visit www.cerevance.com.



Johnna Simoes, ir@cerevance.com


Andrew Mielach, amielach@lifescicomms.com, +1- 646-876-5868